PROFILE OF DRUG USE IN PATIENTS WITH GUILLAIN BARRE SYNDROME (GBS) AT PRIVATE HOSPITAL “X”
Article Sidebar
Published:
Apr 30, 2024
Main Article Content
Abstract
Guillain-Barré syndrome (GBS) or acute inflammatory demyelinating syndrome (AIDP) is an autoimmune disease Acute and complete involvement of the nervous system , especially affecting the root and peripheral nerves , usually precedes infection of the gastrointestinal tract and upper respiratory tract . The treatment received by patients is not something cheap, even if treatment is done too late it will cause death. Objective in this study is
records of drug consumption in Guillain-Barré Syndrome (GBS) patients in Hospital Facilities “X”. This study was a secondary observational and retrospective sampling study of patients with Guillain Barre syndrome(GBS) between 1 January 2019 and 31 December 2022. Results And Conclusions: Total population in this study are 6 patients. The most widely used drug administration pattern in GBS patients was etiological/specific treatment such as immunotherapy in 6 patients (100%) and adjuvant (symptomatic) treatment in the form of medication, neuropsychiatry in 6 patients (100%) and analgesics in 6 patients. Patients who had complications from antibiotics in 1 patients (17%). Patients who received immunotherapy was methylprednisolone (2 x 125 mg) IV in (50%) and dexamethasone (4 x 5 mg – 3 x 5 mg) IV (50%). Patients who received the most pain medication were paracetamol (3x1g) (100%), there is patients using muscle relaxant in 1 patients (16%) and GABA analog (33%). The neurotropic drug most commonly used by patients was mecobalamin (3x500μg) IV was (100%). GBS treatment follows therapy guidelines, and research needs to be carried out regarding the prevalence of recurrence in GBS sufferers
Keywords: GBS, Profil medication, patients Profile.
Article Details
How to Cite
Dewi, F., Ni Putu Desy Ratna W. D, Ni Kadek Sriasih, & IGA. M. Riantarini. (2024). PROFILE OF DRUG USE IN PATIENTS WITH GUILLAIN BARRE SYNDROME (GBS) AT PRIVATE HOSPITAL “X”. Jurnal Farmasi IKIFA, 3(1), 71-84. Retrieved from https://epik.ikifa.ac.id/index.php/jfi/article/view/127
Section
Articles
References
Alter M. The epidemiology of Guillain-Barré syndrome. Ann Neurol. 1990;27:S7–S12. [PubMed] [Google Scholar] [Ref list]
Blum S, Csurhes P, McCombe P. The frequencies of killer immunoglobulin-like receptors and their hla ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in guillian barre syndrome but differ from those of controls, suggesting a role for nk cells in pathogenesis. J Neuroimmunol (2015) 285:53–6. doi: 10.1016/j.jneuroim.2015.05.017
Brannagan TH, III, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology (1996) 47(3):674–7. 10.1212/WNL.47.3.674 [PubMed] [CrossRef] [Google Scholar] [Ref list]
Cerutti A, Cols M, Puga I. Activation of b cells by non-canonical helper signals. EMBO Rep (2012) 13(9):798–810. doi: 10.1038/embor.2012.111 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
Doets AY, Jacobs BC, Doorn PVA. 2018. “Advance in Management of Guillain Barre Syndrome”. Pumed Jurnal, Oct 31 (5): 541-550. https://pubmed.ncbi.nlm.nih.gov/30074496/ .
El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care. 2011;15(4):R164.[PubMed 21745374]
Expert Consensus statements on the use of IVIG in Neurology. 1st ed. Prepared by the Asia Pasific IVIG advisory board.2004
Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21(2)(suppl 1):57-107. doi:10.1016/j.tmrv.2007.01.002[PubMed 17397768]
Feldmeyer L, Benden C, Haile SR, Boehler A, Speich R, French LE, et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol (2010) 90(5):494–7. 10.2340/00015555-0900 [PubMed] [CrossRef] [Google Scholar] [Ref list]
Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol. 2001 Oct;14(5):605–613. [PubMed] [Google Scholar] [Ref list]
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neuro. 1998 Nov;44(5):780–788. [PubMed] [Google Scholar] [Ref list]
Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005 Nov 5;366(9497):1653–1666. [PubMed] [Google Scholar] [Ref list]
Hughes RA, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245–2257. [PubMed] [Google Scholar] [Ref list]
Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997 Dec;176(Suppl 2):S92–S98. [PubMed] [Google Scholar] [Ref list]
Jain, Kewal K. 2011. The Handbook of Neuroprotection. Springer : Humana Press.
Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):8-14.[PubMed 15995024]
Kusuma, Gabriella K. 2013. Studi Penggunaan Obat pada Pasien Guillain-Barre Syndrome (GBS). Fakultas Farmasi Universitas Airlangga.
Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology (2002) 59(12 Suppl 6):S28–32. 10.1212/WNL.59.12_suppl_6.S28 [PubMed] [CrossRef] [Google Scholar] [Ref list]
McCombe PAG JM. Sexual dimorphism in the immune system. In: Rose NRM ,IR, editor. The autoimmune diseases. London: Academic Press; (2020). p. 419–28. [Google Scholar] [Ref list]
McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150–163. [PubMed] [Google Scholar] [Ref list]
McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993 Apr;33(4):333–342. [PubMed] [Google Scholar] [Ref list]
McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 1991;338(8767):593–597. [PubMed] [Google Scholar] [Ref list] (31)
Michon B, et al. Complications of apheresis in children. Transfusion. 2007;47:1837–1842. [PubMed] [Google Scholar] [Ref list]
Mikail, B. 2012. Penderita Guillain Barre Syndrome (GBS) meningkat di Kalangan Usia Produktif. http://health.kompas.com/read/2012/04/14/09265323/Penderita Guillain Barre Syndrome (GBS).Meningkat.di.Kalangan.Usia.Produktif.
Miller, Ariel, Korem, Maya, Almog, Ronit dan Galboiz, Yanina. 2005. Vitamin B12, Demylination, Remyelination and Repair in Multiple Sclerosis. Journal of the Neurological Science, Vol.233, p.93-97.
Mishra A, G. Sai Khrisna, T. Komal Krishna. Guillain-Barre syndrome: an orphan disease. World journal of pharmaceutical research. 2017;6(5):393-400
Nunn CL, Lindenfors P, Pursall ER, Rolff J. On sexual dimorphism in immune function. Philos Trans R Soc London Ser B Biol Sci (2009) 364(1513):61–9. doi: 10.1098/rstb.2008.0148 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000 Oct;48(4):624–631. [PubMed] [Google Scholar] [Ref list]
Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007 Jan 24;(1) CD004761. [PMC free article] [PubMed] [Google Scholar] [Ref list]
Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhoodGuillain-Barré syndrome: a reappraisal. Ann Neurol. 1999 Nov;46(5):701–707. [PubMed] [Google Scholar] [Ref list]
Pioli PC,M, Kornas M, Renner P, Pioli K-A. Sex dictates organ-specific differences in the production and activation of plasmablasts and plasma cells. J Immunol (2021) 206(98). [Google Scholar] [Ref list]
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-33. [PMC free article] [PubMed] [Reference list]
van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barré syndrome: randomised trial. Lancet. 2004;363:192–196. doi: 10.1016/S0140-6736(03)15324-X. [PubMed] [CrossRef] [Google Scholar] [Ref list]
Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000 Feb 8;54(3):620–625. [PubMed] [Google Scholar] [Ref list]
Yang M, Peyret C, Shi XQ, Siron N, Jang JH, Wu S, et al.. Evidence from human and animal studies: Pathological roles of Cd8(+) T cells in autoimmune peripheral neuropathies. Front Immunol (2015) 6:532. doi: 10.3389/fimmu.2015.00532 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
Yin PQ, Sun YY, Chen HP, Li GZ, Zhong D. Genome-wide gene expression analysis of peripheral leukocytes in relation to the Male predominance of Guillain-barre syndrome: Differential gene expression between Male and female patients. Int J Neurosci (2016) 126(6):531–41. doi: 10.3109/00207454.2015.1044088 [PubMed] [CrossRef] [Google Scholar] [Ref list]
Zhang, gang, Lehmann, Helmar C., Bogdanova, Nataliia, Gao, Tong, Zhang, Jiangyang, and Sheikh, Kazim A. 2011. Erythropoietin Enhances Nerve Repair in Anti-Ganglioside Antibody-Mediated Models of Immune Neuropathy. Plos ONE Vol.6 No.10 e27067.doi:10.1371/journal.pone.0027067, p.1-12
Blum S, Csurhes P, McCombe P. The frequencies of killer immunoglobulin-like receptors and their hla ligands in chronic inflammatory demyelinating polyradiculoneuropathy are similar to those in guillian barre syndrome but differ from those of controls, suggesting a role for nk cells in pathogenesis. J Neuroimmunol (2015) 285:53–6. doi: 10.1016/j.jneuroim.2015.05.017
Brannagan TH, III, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology (1996) 47(3):674–7. 10.1212/WNL.47.3.674 [PubMed] [CrossRef] [Google Scholar] [Ref list]
Cerutti A, Cols M, Puga I. Activation of b cells by non-canonical helper signals. EMBO Rep (2012) 13(9):798–810. doi: 10.1038/embor.2012.111 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
Doets AY, Jacobs BC, Doorn PVA. 2018. “Advance in Management of Guillain Barre Syndrome”. Pumed Jurnal, Oct 31 (5): 541-550. https://pubmed.ncbi.nlm.nih.gov/30074496/ .
El-Bayoumi MA, El-Refaey AM, Abdelkader AM, El-Assmy MM, Alwakeel AA, El-Tahan HM. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care. 2011;15(4):R164.[PubMed 21745374]
Expert Consensus statements on the use of IVIG in Neurology. 1st ed. Prepared by the Asia Pasific IVIG advisory board.2004
Feasby T, Banwell B, Benstead T, et al. Guidelines on the use of intravenous immune globulin for neurologic conditions. Transfus Med Rev. 2007;21(2)(suppl 1):57-107. doi:10.1016/j.tmrv.2007.01.002[PubMed 17397768]
Feldmeyer L, Benden C, Haile SR, Boehler A, Speich R, French LE, et al. Not all intravenous immunoglobulin preparations are equally well tolerated. Acta Derm Venereol (2010) 90(5):494–7. 10.2340/00015555-0900 [PubMed] [CrossRef] [Google Scholar] [Ref list]
Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol. 2001 Oct;14(5):605–613. [PubMed] [Google Scholar] [Ref list]
Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neuro. 1998 Nov;44(5):780–788. [PubMed] [Google Scholar] [Ref list]
Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005 Nov 5;366(9497):1653–1666. [PubMed] [Google Scholar] [Ref list]
Hughes RA, et al. Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain. 2007;130:2245–2257. [PubMed] [Google Scholar] [Ref list]
Hughes RA, Rees JH. Clinical and epidemiologic features of Guillain-Barré syndrome. J Infect Dis. 1997 Dec;176(Suppl 2):S92–S98. [PubMed] [Google Scholar] [Ref list]
Jain, Kewal K. 2011. The Handbook of Neuroprotection. Springer : Humana Press.
Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics. 2005;116(1):8-14.[PubMed 15995024]
Kusuma, Gabriella K. 2013. Studi Penggunaan Obat pada Pasien Guillain-Barre Syndrome (GBS). Fakultas Farmasi Universitas Airlangga.
Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology (2002) 59(12 Suppl 6):S28–32. 10.1212/WNL.59.12_suppl_6.S28 [PubMed] [CrossRef] [Google Scholar] [Ref list]
McCombe PAG JM. Sexual dimorphism in the immune system. In: Rose NRM ,IR, editor. The autoimmune diseases. London: Academic Press; (2020). p. 419–28. [Google Scholar] [Ref list]
McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review. Neuroepidemiology. 2009;32(2):150–163. [PubMed] [Google Scholar] [Ref list]
McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993 Apr;33(4):333–342. [PubMed] [Google Scholar] [Ref list]
McKhann GM, Cornblath DR, Ho T, et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China. Lancet. 1991;338(8767):593–597. [PubMed] [Google Scholar] [Ref list] (31)
Michon B, et al. Complications of apheresis in children. Transfusion. 2007;47:1837–1842. [PubMed] [Google Scholar] [Ref list]
Mikail, B. 2012. Penderita Guillain Barre Syndrome (GBS) meningkat di Kalangan Usia Produktif. http://health.kompas.com/read/2012/04/14/09265323/Penderita Guillain Barre Syndrome (GBS).Meningkat.di.Kalangan.Usia.Produktif.
Miller, Ariel, Korem, Maya, Almog, Ronit dan Galboiz, Yanina. 2005. Vitamin B12, Demylination, Remyelination and Repair in Multiple Sclerosis. Journal of the Neurological Science, Vol.233, p.93-97.
Mishra A, G. Sai Khrisna, T. Komal Krishna. Guillain-Barre syndrome: an orphan disease. World journal of pharmaceutical research. 2017;6(5):393-400
Nunn CL, Lindenfors P, Pursall ER, Rolff J. On sexual dimorphism in immune function. Philos Trans R Soc London Ser B Biol Sci (2009) 364(1513):61–9. doi: 10.1098/rstb.2008.0148 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol. 2000 Oct;48(4):624–631. [PubMed] [Google Scholar] [Ref list]
Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff's brainstem encephalitis and related disorders. Cochrane Database Syst Rev. 2007 Jan 24;(1) CD004761. [PMC free article] [PubMed] [Google Scholar] [Ref list]
Paradiso G, Tripoli J, Galicchio S, Fejerman N. Epidemiological, clinical, and electrodiagnostic findings in childhoodGuillain-Barré syndrome: a reappraisal. Ann Neurol. 1999 Nov;46(5):701–707. [PubMed] [Google Scholar] [Ref list]
Pioli PC,M, Kornas M, Renner P, Pioli K-A. Sex dictates organ-specific differences in the production and activation of plasmablasts and plasma cells. J Immunol (2021) 206(98). [Google Scholar] [Ref list]
Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-33. [PMC free article] [PubMed] [Reference list]
van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barré syndrome: randomised trial. Lancet. 2004;363:192–196. doi: 10.1016/S0140-6736(03)15324-X. [PubMed] [CrossRef] [Google Scholar] [Ref list]
Van Koningsveld R, Van Doorn PA, Schmitz PI, Ang CW, Van der Meché FG. Mild forms of Guillain-Barré syndrome in an epidemiologic survey in The Netherlands. Neurology. 2000 Feb 8;54(3):620–625. [PubMed] [Google Scholar] [Ref list]
Yang M, Peyret C, Shi XQ, Siron N, Jang JH, Wu S, et al.. Evidence from human and animal studies: Pathological roles of Cd8(+) T cells in autoimmune peripheral neuropathies. Front Immunol (2015) 6:532. doi: 10.3389/fimmu.2015.00532 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
Yin PQ, Sun YY, Chen HP, Li GZ, Zhong D. Genome-wide gene expression analysis of peripheral leukocytes in relation to the Male predominance of Guillain-barre syndrome: Differential gene expression between Male and female patients. Int J Neurosci (2016) 126(6):531–41. doi: 10.3109/00207454.2015.1044088 [PubMed] [CrossRef] [Google Scholar] [Ref list]
Zhang, gang, Lehmann, Helmar C., Bogdanova, Nataliia, Gao, Tong, Zhang, Jiangyang, and Sheikh, Kazim A. 2011. Erythropoietin Enhances Nerve Repair in Anti-Ganglioside Antibody-Mediated Models of Immune Neuropathy. Plos ONE Vol.6 No.10 e27067.doi:10.1371/journal.pone.0027067, p.1-12